Abstract 219P
Background
We assessed the use and outcomes of first-, second- and third-line chemotherapy in patients diagnosed with hormone receptor-positive/HER2-negative (HR+/HER2-) advanced breast cancer (ABC).
Methods
All consecutively diagnosed patients with HR+/HER2-ABC in 2007-2020 in ten Dutch hospitals were retrieved from the SONABRE registry (NCT-03577197). Last follow-up was collected in 2022. The proportion of patients starting a specific line of chemotherapy was assessed using the competing risk method. Median progression-free survival (PFS) and overall survival (OS) were calculated from start of chemotherapy using the Kaplan-Meier method.
Results
Of the 3146 patients diagnosed with HR+/HER2-ABC, 54% started a first-, 32% a second- and 18% a third-line of chemotherapy within 120 months from diagnosis, regardless of prior endocrine-based therapy. At start of first-, second- and third-line of chemotherapy, median age was respectively 63, 61 and 60 years, 73%, 78% and 71% had a WHO performance status of 0-1, 48%, 51% and 47% received chemotherapy in the (neo)adjuvant setting, and 80%, 88% and 91% had visceral metastases. When chemotherapy started in 2014-2022, first-, second- and third-line chemotherapy comprised capecitabine in respectively 54%, 35% and 19%, taxanes in 29%, 34% and 24%, and an AC-containing regimen in 12%, 6% and 5% of patients. Median PFS and OS were 6.7 and 15.9 months from starting first-line, 4.9 and 10.5 months from starting second-line and 3.9 and 8.2 months from starting third-line chemotherapy.
Conclusions
Patients diagnosed with HR+/HER2-ABC with an indication for chemotherapy have advanced disease and a poor prognosis. Capecitabine and taxanes were most often used in the first three lines of chemotherapy.
Legal entity responsible for the study
The authors.
Funding
The SONABRE Registry is supported by Novartis BV; Roche; Pfizer; Eli Lilly & Co.; Daiichi Sankyo; Gilead and AstraZeneca. Funding sources had no role in the conceptualization or writing of the abstract.
Disclosure
S.M.E. Geurts: Financial Interests, Institutional, Funding: Novartis BV, Roche, Pfizer, Ely Lilly, Daiichi Sankyo, Gilead, AstraZeneca; Financial Interests, Personal, Invited Speaker: AstraZeneca. M. Meegdes: Financial Interests, Institutional, Funding: Novartis BV, Roche, Pfizer, Eli Lilly, Daiichi Sankyo, Gilead, AstraZeneca. A. Fallois: Financial Interests, Institutional, Funding: Novartis BV, Roche, Pfizer, Eli Lilly, Daiichi Sankyo, Gilead. I.J.H. Vriens: Financial Interests, Institutional, Funding: AstraZeneca; Financial Interests, Institutional, Research Grant: Pfizer. V.C.G. Tjan-Heijnen: Financial Interests, Personal, Advisory Board: E Lilly, AstraZeneca, Novartis; Financial Interests, Institutional, Research Grant: E Lilly, Novartis, Pfizer, AstraZeneca, Roche, Gilead. All other authors have declared no conflicts of interest.